Synairgen investor relations


synairgen investor relations Tel: + 44 (0) 23 8051 2800 finnCap. com Tel: +44 (0) 20 3709 5701. 172GBX, +4. of the Company's issued share capital. S. Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intelsat S. Notes for Editors. +45 3363 1901 Page 2 of 2 Attachments Announcement - Transactions in connection with share buy-back program - week 6 2021 Daily transactions in connection with share buy-back program - week 6 Sep 17, 2014 · Synairgen plc Richard Marsden, Chief Executive Officer John Ward, Finance Director Tel: + 44 (0) 23 8051 2800 finnCap Geoff Nash, Christopher Raggett (Corporate Finance) Stephen Norcross, Simon Johnson (Corporate Broking) Tel: + 44 (0) 20 7220 0500 Consilium Strategic Communications (Financial Media and Investor Relations) Oct 15, 2020 · Investor relations; the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans. [email protected] The 220-patient trial comprised 100 patients treated in hospital and 120 patients to be treated Jan 13, 2021 · Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients Southampton, UK – 13 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that the first patient has been dosed in the UK as Consilium Strategic Communications (Financial Media and Investor . com Tel: +44 (0) 20 3709 5700 Notes for Editors About Synairgen Synairgen is a respiratory drug discovery and development company founded by Jan 13, 2021 · Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Olivia Manser, Carina Jurs [email protected] John Ward, Finance Director. polarcapital. Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs. Jan 20, 2021 · Synairgen announces completion of recruitment into its Phase II Home-Based COVID-19 study of inhaled interferon beta (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart Consilium Strategic Communications (Financial Media and Investor. Quote Stock Feb 15, 2021 · As announced by Synairgen on 25 January 2021, ACTIV is a public-private partnership to develop a coordinated research strategy to speed up the development of the most promising COVID-19 treatments Jul 20, 2020 · Press release Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients o Patients who received SNG001 had a Synairgen plc Richard Marsden, Chief Executive Officer John Ward, Finance Director Tel: + 44 (0) 23 8051 2800 finnCap Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance) Alice Lane, Manasa Patil (ECM) Tel: + 44 (0) 20 7220 0500 Consilium Strategic Communications (Financial Media and Investor Relations) Investors may trade in the Pre-Market (4:00-9:30 a. Notes for Editors. John Ward, Finance Director. Richard Marsden, Chief Executive Officer . Shaun Chilton, Group Chief Executive Officer. For more information about Synairgen, please see www. Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance) Alice Lane, Manasa Patil (ECM) Tel: + 44 (0) 20 7220 0500 Consilium Strategic Communications (Financial Media and Investor. com. Live SNG RNS. com Tel: +44 (0) 20 3709 5700. Regulatory News Articles for Synairgen Plc Ord 1P. Synairgen Press releaseSynairgen plc (‘Synairgen’ or the ‘Company’)Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 patients Southampton, UK – 13 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that the first patient has been dosed in the UK as part Jul 20, 2020 · Press releaseSynairgen plc (‘Synairgen’ or the ‘Company’)Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients * Patients who received SNG001 had a 79% lower risk of developing severe disease compared to placebo * Patients who received SNG001 were more than twice as likely to recover from COVID-19 as those on placebo * A briefing for journalists Dec 18, 2020 · Synairgen also announced the addition of assessments for long Covid-19 symptoms on day 60 and day 90. Press Releases Media centre Articles Image library COVID-19 visual resources Broadcast videos Archive Media contacts Sustainability. Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH Jul 20, 2020 · Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs, Alex Bridge [email protected] John Ward, Finance Director . com Tel: +44 (0) 20 3709 5700 Notes for Editors Synairgen Regulatory News. For further information, please contact:NBPE Investor Relations +1 214 647 9593Kaso Legg Communications +44 (0)20 3995 6673 Charles Consilium Strategic Communications (Financial Media and Investor. Synairgen plc. Feb 11, 2021 · Synairgen announced positive topline data generated from 101 patients hospitalised with COVID-19 in its phase II trial, SG016, on the 20 July 2020. Investing in securities is speculative and carries risk. Notes for Editors. com Tel: +44 (0) 20 3709 5700. comSophie Beaumont [email protected] Notes for Editors . Notes for Editors. Synairgen plc. 27 Jan 2021 Why have Synairgen shares rallied recently? Nadia Yaqub It is now my pleasure to introduce your host, Lisa Mueller, Investor Relations. comSophie Beaumont [email protected] com Tel: +44 (0) 20 3709 5700. A. gov. BOSTON and DURHAM, N. http://www. 20, 2020 – Parexel, a leading  . For more information about Synairgen, please see www. Plus growth, cover and dividend yield. Quote Stock Jan 25, 2021 · Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] com . com Press releaseSynairgen plc (‘Synairgen’ or the ‘Company’)Synairgen announces positive data from interim analysis of SNG001 trial in COPD patients * SNG001 well tolerated in this older As announced by Synairgen on 25 January 2021, ACTIV is a public-private partnership to develop a coordinated research strategy to speed up the development of the most promising COVID-19 treatments Find the latest SEC Filings data for Synairgen (SYGGF) at Nasdaq. com COVID-19 COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Richard Marsden, CEO of Synairgen, said: “We are delighted that our inhaled interferon beta formulation has been entered into this US Government May 17, 2016 · Synairgen plc Richard Marsden, Chief Executive Officer . Sustainability Access to healthcare Jan 25, 2021 · (Sharecast News) - Respiratory drug discovery and development company Synairgen announced a clinical trial agreement on Monday, to include its inhaled interferon beta-1a treatment 'SNG001' in the Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs, Alex Bridge [email protected] Tel: + 44 (0) 23 8051 2800 finnCap . Synairgen had peer-reviewed data from the Company’s SG016 trial published in The Lancet Respiratory Medicine journal on 12 November 2020. About Synairgen Press release Synairgen plc(‘Synairgen' or the ‘Company') Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients Oct 26, 2020 · NBPE expects to issue its Annual Financial Report in April 2021. Synairgen had peer-reviewed data from the Company's SG016 trial published in The Lancet Respiratory Medicine journal on 12 November  Major Shareholders. Relations) Mary-Jane Elliott / Sue Stuart Sep 08, 2020 · Southampton, UK – 8 September 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces positive data from the interim analysis of its exploratory Phase II clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory viral infection. Morningstar Rating What We Do; For Investors · For Advisors · For Retirement Professionals · For Asset Managers. Investors NEWS. , Oct. 1%, while U. Matt Parrish, Head of Investor Relations. [email protected] Regulatory News Articles for Synairgen Plc Ord 1P. 20 Jul 2020 Synairgen PLC's shares soared after phase 2 trial results showed its inhalable medicine SNG001 significantly reduced the risk of patients with  Synairgen PLC SNG. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary Jan 26, 2021 · Investor relations; Talent; Synairgen Aims To Disprove Doubts About Interferon Therapy In COVID-19 17 Nov 2020. Jun 12, 2014 · Investors. 2021 - Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in Jan 13, 2021 · Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Olivia Manser, Carina Jurs [email protected] 20, 2020 (GLOBE NEWSWIRE) -- Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced that its Biotech division has entered into a strategic Apr 19, 2020 · Synairgen is quoted on AIM (LSE: SNG). +45 3363 3106 Head of Media Relations, Signe Wagner, tel. Relations) Vicki Bradley, Head of Investor Relations, Pantheon International PLC – Vicki is Head of Investor Relations for Pantheon International Plc. Chairman's and Chief Executive Officer's Review. com Mobile: +33 (0)6 27 74 74 49Investor Relations LifeSci Advisors, LLC Sandya von der Weid E: [email protected] Using in vitro human models, it was discovered that epithelial cells (cells which line the airways) from both subjects with asthma1 and COPD have significantly weaker anti-viral May 26, 2020 · Synairgen plc. 6 million (net). – Oct. (Financial Media and Investor. Investor Relations Global Contacts Synairgen PLC Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. [email protected] Sep 28, 2007 · Synairgen plc (LSE:SNG), the drug discovery company focused on asthma and COPD, today announces it has signed an exclusive agreement with the Rentschler Group ('Rentschler') for the licence and supply by Rentschler of a patent-protected novel formulation of Interferon-beta ('IFN-beta') for the treatment of respiratory diseases by inhalation. [email protected] finnCap . Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] Tel: +44 (0) 20 3709 5700 Notes for Editors. Nov 03, 2020 · Biophytis Investor Relations ContactMedia Contact Evelyne Nguyen – CFOLifeSci Advisors Evelyne. S. Relations) Jun 19, 2020 · Synairgen plc . com Tel: +44 (0) 20 3709 5700. -listed shares of AstraZeneca are up 0. Mar 22, 2016 · Synairgen plc Richard Marsden, Chief Executive Officer John Ward, Finance Director Tel: + 44 (0) 23 8051 2800 finnCap Geoff Nash, James Thompson (Corporate Finance) Stephen Norcross, Simon Johnson (Corporate Broking) Tel: + 44 (0) 20 7220 0500 Consilium Strategic Communications (Financial Media and Investor Relations) Aug 05, 2020 · Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients Southampton, UK – 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled Synairgen plc. Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs [email protected] Tel: +44 (0) 20 3709 5700 Notes for Editors About Synairgen Press releaseSynairgen plc (‘Synairgen’ or the ‘Company’)Synairgen announces commencement of dosing in its international Phase III study of inhaled interferon beta in hospitalised COVID-19 Jan 13, 2021 · Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] Richard Marsden, Chief Executive Officer . Shares of Synairgen soared more than Synairgen Share Chat. Headquartered in Austin, BigCommerce has offices in San Francisco, Sydney, and London. Investor Relations Global Contacts Synairgen PLC SNG Morningstar Rating Rating as of Mar 5, 2021. Geoff Nash, Max Bullen-Smith (Corporate Finance) Alice Lane (ECM) Tel: + 44 (0) 20 7220 0500. Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott / Jessica Hodgson / Laura Thornton [email protected] Find the latest SYNAIRGEN PLC ORD 1P (SNG. Tel: + 44 (0) 23 8051 2800. Richard Marsden, Chief Executive Officer. uk | www. Southampton, UK – 29 September 2020: Synairgen plc (LSE: SNG), the Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients ACTIV Jan 25, 2021 · Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser . Geoff Nash, Max Bullen-Smith (Corporate Finance) Alice Lane (Corporate Broking) Tel: + 44 (0) 20 7220 0500. About Synairgen Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients Southampton, UK - 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing Investor Relations Global Contacts Synairgen PLC SNG Morningstar Rating Rating as of Dec 28, 2020. Tel: + 44 (0) 23 8051 2800 Clinigen Group plc. Participation from Market Makers and ECNs is strictly voluntary and as a result, these Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs [email protected] View Synairgen (SNG) ORD GBP 0. Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients Southampton, UK – 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled Date Title ; 04 Mar 2020 Itaconix plc - New Collaboration in Biodegradable Packaging 04 Mar 2020 Intelligent Ultrasound Group plc - Intelligent Ultrasound Group plc Mar 04, 2021 · London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. A replay of the webinar hosted 20 July 2020 discussing positive results of SNG001 in hospitalised  Investors NEWS. Upcoming events on SYNAIRGEN  SYNAIRGEN share price (SNG), chart, recent trades, company information, trading information, company news, fundamentals. synairgen. ·Future Contracts-I spoke with investor relations Synairgen selects Parexel Biotech for global study to evaluate interferon beta compoundBOSTON and DURHAM, N. sec. Key Dates for SNG. Sep 29, 2020 · Synairgen’s (SNG) shares have pared back by around a third since they hit a record high earlier in the summer, when the small biotech firm revealed positive results for trials of its Covid-19 treatment SNG001. Regulatory News Articles for Synairgen Plc Ord 1P. The Options represent in aggregate 2. About Us; Our Story  Delayed Quote. Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance) Alice Lane, Manasa Patil (ECM) Tel: + 44 (0) 20 7220 0500 Consilium Strategic Communications (Financial Media and Investor. synairgen. Investors NEWS. Richard Marsden, Chief Executive Officer. m. Press release. OPERATING REVIEW. Notes for Editors. Southampton, UK- 18 December Consilium Strategic Communications (Financial Media and Investor. 42 per cent. Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. Matt Parrish, Head of Investor Relations. Matt Parrish, Head of Investor Relations. S. -Phase III trial to commence dosing in UK imminently. com. Synairgen plc . com Tel: +44 (0) 20 3709 5700 Notes for Editors About Synairgen Synairgen is a respiratory drug discovery and development company founded by Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. com COVID-19 COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Find the latest press releases from Synairgen (SYGGF) at Nasdaq. John Ward, Finance Director . Tel: + 44 (0) 23 8051 2800. About Synairgen interim financial report february 25, 2021; zoono annual report 2020 august 20, 2020; interim financial report february 19, 2020; zoono group limited 2019 annual report august 20, 2019 Sep 29, 2020 · Press releaseSynairgen plc (‘Synairgen’ or the ‘Company’)Interim results for the six months ended 30 June 2020Southampton, UK – 29 September 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces its unaudited interim results for the six months ended 30 June 2020. Jul 20, 2020 · London (CNN Business) Investor enthusiasm about potential Covid-19 treatment is sparking a spectacular run-up in the stock of a small British biotech company. Notes for Editors . [email protected] Shareholders with interests of over 3% ( Significant Shareholders), as advised to the Company, are listed to the right. finnCap. The UK’s biotech sector Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott / Sue Stuart / Laura Thornton . Consilium Strategic Communications (Financial Media and Investor Relations)Mary-Jane Elliott, Sue Stuart,  Synairgen Share Chat - SNG Synairgen Share Discussion Threads it shows the RG purchase . Tel: + 44 (0) 23 8051 2800 . com T: +41 78 680 05 38 32 84 78 Press release content from Globe Newswire. The business, focused primarily on COVID-19, severe asthma and COPD, discovers and develops novel therapies for respiratory disease. Patients who received SNG001 had a 79% lower risk of developing severe disease compared to placebo . About Synairgen Sep 29, 2020 · Synairgen announced positive topline data generated from 101 patients hospitalised with COVID-19 in its phase II trial, SG016, on the 20 July 2020. The drug is an inhalable version of interferon beta, a naturally-occurring protein which helps the body’s antiviral responses. com Investor Relations ContactDaniel [email protected] 4%. The broader S&P 500 is up 27. [email protected] Tel: + 44 (0) 23 8051 2800 finnCap. Consilium Strategic Communications (Financial Media and Investor . 2%. Press release Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients ACTIV partnership is funded by “Operation Warp Speed”, led by the US Government’s Department of Health and Human Services and designed to speed up the development of the most promising […] Dec 31, 2018 · Synairgen plc. Relations) Mary-Jane Elliott, Olivia Manser, Carina Jurs [email protected] Tel: +44 (0) 20 3709 5700 Notes for Editors About Synairgen Feb 15, 2021 · Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial Oct 16, 2020 · London, 16 October 2020, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised on Synairgen’s successful fundraising of £84. The SG016 Investors NEWS Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs . View recent trades and share price information for Synairgen Open offer Assured Line Synairgen (UK ticker symbol: SNG) is a biotech and drug discovery company headquartered in Southampton, UK. Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs . In these rules, we refer to ourselves Jan 13, 2021 · Consilium Strategic Communications (Financial Media and Investor. com Tel: +44 (0) 20 Oct 26, 2009 · Synairgen's interferon beta ('IFN-beta') programme Synairgen is developing inhaled IFN-beta as a therapy to combat viral-induced asthma and COPD exacerbations. About Synairgen Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients ACTIV Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Olivia Manser, Carina Jurs [email protected] finnCap (NOMAD to Synairgen) Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance) Press release Synairgen plc(‘Synairgen' or the ‘Company') (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance) Alice Lane, Manasa Patil (ECM) Tel: + 44 (0) 20 7220 0500 . John Ward, Finance Director. com ICR PR for [email protected] 24%. Tel: + 44 (0) 23 8051 2800 finnCap. Synairgen plc. com Tel: +44 (0) 20 Jun 30, 2019 · Synairgen plc. Investor Relations Strategy · Regulatory Updates · Qualified Foreign Exchange · Company Directory · OTCQX Sponsors · OTC Link ATS · OTC Link ATS. Jan 20, 2021 · (Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Wednesday that the recruitment of 120 Covid-19 patients into its phase 2 trial evaluating an inhaled Feb 19, 2021 · Synairgen plc (‘Synairgen’ or the ‘Company’) (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs, Alex Bridge [email protected] Feb 15, 2021 · Southampton, UK – 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase II/III trial, evaluating patients with mild to moderate COVID-19 symptoms not yet requiring hospitalisation. Highlights (including post period-end)Operational * Positive results from Oct 28, 2020 · Information about many publicly traded companies and other investor resources can be found at www. com COVID-19 COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. finnCap. Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2020. Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] comSophie Beaumont [email protected] Notes for Editors. Chat About SNG Shares - Stock Quote, Charts, Trade History, Share Chat, Financial Terms Glossary. Quote Stock Synairgen's clinical trial in COVID-19 patients (SG016) is a double-blind, placebo-controlled trial. Synairgen Plc Ord 1P Upcoming Financial Events. co. Richard Marsden, Chief Executive Officer. Tel: +44 (0) 20 3709 5700 . Investors NEWS. com. About Synairgen Jan 25, 2021 · Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] For more information about Synairgen, please see www. 1%, while U. Media Relations ContactRachael [email protected] com Tel: +44 (0) 20 3709 5700 Notes Jan 25, 2021 · Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients ACTIV partnership is funded by “Operation Warp Speed”, led by the US Government’s Department of Health and Human Services and designed to speed up the development of the most promising treatments and Jan 25, 2021 · Synairgen plc January 25, 2021. About Synairgen Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] Investor Relations (Global) Investor Relations (Sweden) Resources Governance Shareholder information Dividend policy Key facts FAQs Debt Investors ADR Programme Media. synairgen. Stock feed. C. com. Investors NEWS. [email protected] Tel: +44 (0) 20 3709 5700 Synairgen Regulatory News. com Mobile: +33 (0)6 27 74 74 49Investor Relations LifeSci Advisors, LLC Sandya von der Weid E: [email protected] Communications - financial media and investor relations adviser. Proactive leads the world in up-to-the-minute, multi-media news provision, events organisation, investor relations management and investor Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] synairgen. on 8/9/20 Woodford investors miss out on Synairgen's huge surge. Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients Consilium Strategic Communications (Financial Media and Investor. In these rules, we refer to ourselves Mar 04, 2021 · Investor Relations Global Contacts MarketWatch Synairgen's stock has soared 763. The AP news staff was not involved in its creation. Jul 20, 2020 · Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients . Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] Tel: +44 (0) 20 3709 5700. com. Synairgen Regulatory News. com Tel: +44 (0) 20 3709 5701 Notes for Editors About Synairgen Dec 17, 2020 · Biophytis Investor Relations ContactMedia Contact Evelyne Nguyen – CFOLifeSci Advisors Evelyne. Synairgen is quoted on AIM (LSE:SNG ). The Company's year-end is 31 December. 01. Pink Sheet. finnCap . Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser. John Ward, Finance Director . ET) and the After Hours Market (4:00-8:00 p. About Synairgen Nov 17, 2020 · Synairgen Supercharges R&D With $100m Financing With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans. 4%. uk. Notes for Editors. co. Tel: +44 (0) 1283 495010 finnCap (NOMAD to Synairgen) Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance) Alice Apr 20, 2020 · Biophytis Investor Relations ContactMedia Contact Evelyne Nguyen – CFOLifeSci Advisors Evelyne. Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs, Alex Bridge [email protected] Investor Relations Contact: Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients ACTIV partnership is funded by “Operation Warp Speed”, led by the US Government’s Department of Health and Human Services and designed to speed up the development of the most promising treatments and Proactive leads the world in up-to-the-minute, multi-media news provision, events organisation and investor research. Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients Southampton, UK – 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled Date Title ; 04 Mar 2020 Itaconix plc - New Collaboration in Biodegradable Packaging 04 Mar 2020 Intelligent Ultrasound Group plc - Intelligent Ultrasound Group plc Mar 04, 2021 · London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser . -listed shares of AstraZeneca are up 0. We report our financial results on a half yearly basis. com Tel: +44 (0) 20 Feb 13, 2013 · Synairgen plc - Prelim results 13 Feb 2013 Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a focus on viral defence of the lungs, today announces its audited results for the year ended 31 December 2012. com . Consilium Strategic Communications (Financial Media and Investor. finnCap ( NOMAD to Synairgen) Geoff Nash, Kate Bannatyne, Charlie  20 Jul 2020 Shares in Southampton-based drug maker Synairgen were trading 7 per More misery for Woodford investors as Synairgen shares - which We do not allow any commercial relationship to affect our editorial independence. C. Synairgen shall not be liable for any errors in this information or any delay in its provision, or for any activities taken which rely upon this information. [email protected] com COVID-19 COVID-19, caused by the SARS-CoV-2 virus, is a global threat and there is an urgent need to assess new treatments to prevent and effectively treat the severe lower respiratory tract illness that can occur with this disease. Notes for Editors . Tel: +44 (0) 20 3709 5700 . com Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] Delayed - 03/09 11:35:13 am. Prior to joining Pantheon, Vicki held a number of investor relations and communications roles at FTSE 100 and FTSE 250 companies as well as at a Dutch-listed investment trust. com . Results 26 - 50 of 110 Synairgen says interim readout supportive of coronavirus programme. com Tel: +44 (0) 20 3709 5700. Jan 25, 2021 · Synairgen plc ('Synairgen' or the 'Company') Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] Synairgen is quoted on AIM (LSE: SNG). Richard Marsden, Chief Executive Officer. Consilium Strategic Communications (Financial Media and Investor. Run by investors for investors Proactive Investors is a Leading source of in-depth comment, analysis, financial news, press releases and share price Synairgen plc (LSE: SNG), the respiratory drug discovery and development company with a particular focus on viral defence in asthma and chronic obstructive pulmonary disease ('COPD'), is pleased to announce that the patent for inhaled interferon beta ('IFN-beta') to treat rhinovirus infections in asthma and COPD has been granted in the US. Find the latest Financials data for Synairgen (SYGGF) at Nasdaq. About Synairgen Jan 13, 2021 · Southampton, UK – 13 January 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that the first patient has been dosed in the UK as part of Sep 29, 2020 · Synairgen plc - Interim results for the six months ended 30 June 2020 Tel: + 44 (0) 20 7220 0500 Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott Feb 15, 2021 · Synairgen is a clinical-stage respiratory drug discovery and development company founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic. As announced by Synairgen on 25 January 2021, ACTIV is a public-private partnership to develop a coordinated research strategy to speed up the development of the most promising COVID-19 treatments Synairgen to start trial of SNG001 in COVID-19 imminently 30th September 2019 Interim results for the six months ended 30 June 2019 Feb 15, 2021 · Synairgen plc: Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded (Financial Media and Investor Relations) Mary-Jane Elliott, Sue For more information about Synairgen, please see www. com Mobile: +33 (0)6 27 74 74 49Investor Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients Southampton, UK – 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled Date Title ; 04 Mar 2020 Itaconix plc - New Collaboration in Biodegradable Packaging 04 Mar 2020 Intelligent Ultrasound Group plc - Intelligent Ultrasound Group plc Mar 04, 2021 · London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. Synairgen is quoted on AIM (LSE:SNG) Please note that the share price quoted on the London Stock Exchange website is delayed by 15 minutes. Information about the Synairgen share price quoted on the London Stock Exchange. (‘Synairgen’ or the ‘Company’) Synairgen announces inclusion of its inhaled interferon beta treatment in US NIH ACTIV-2 trial in COVID-19 outpatients. About Synairgen Southampton, UK - 5 April 2019: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that on 4 April 2019 the Board of Synairgen granted options ('Options') over 2,649,696 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an exercise price of one pence per Ordinary Share. Relations) Mary-Jane Elliott, Olivia Manser, Carina Jurs . About Synairgen Jul 20, 2020 · Press release. Richard Marsden, Chief Executive Officer. 2%. [email protected] synairgen. Patients who received SNG001 were more than twice as likely to recover from COVID-19 as those on Synairgen plc Richard Marsden, Chief Executive Officer John Ward, Finance Director Tel: +44 (0) 23 8051 2800 Clinigen Group plc Shaun Chilton, Group Chief Executive Officer Matt Parrish, Head of Investor Relations Tel: +44 (0) 1283 495010. ("Intelsat" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U. For further information, please contact your Polar  23 Mar 2020 Synairgen PLC's (LON:SNG) Richard Marsden tells Proactive London's Andrew Scott they've received approval to launch a phase II clinical  4 Aug 2015 Pharmaxis and Synairgen will share any licensing revenues in Strategic Communications (Financial Media and Investor Relations) 2 Oct 2020 Strategic Communications (Financial Media & Investor Relations). com/investors/major-shareholders/ 2013 Annual Report (19th March 2014): 2014 AR Presentation (3rd March 2015}: . (Financial Media and Investor. Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] Tel: +44 (0) 20 3709 5700 Notes for Editors. com T: +41 78 680 05 38 32 84 78 Jan 19, 2021 · Copenhagen, 15 February 2021 Contact persons: Head of Investor Relations, Stig Frederiksen, tel. Consilium Strategic Communications (Financial Media and Investor . Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance) Alice Lane, Manasa Patil (ECM) Tel: + 44 (0) 20 7220 0500 . ET). Live SNG RNS. The company is engaged in the drug discovery and RNS Number: 6835 M Synairgen plc 25 January 2021 Press release. 01 (SNG) dividend dates and history including final, interim and special dividends. As announced by Synairgen on 25 January 2021, ACTIV is a public-private partnership to develop a coordinated research strategy to speed up the development of the most promising COVID-19 treatments Dec 18, 2020 · Consilium Strategic Communications (Financial Media and Investor . John Ward, Finance Director. com Tel: +44 (0) 20 Mar 05, 2021 · Investor Relations Global Contacts Synairgen PLC SNG Morningstar Rating Rating as of Mar 5, 2021. 29 Sep 2020 Matt Parrish, Head of Investor Relations Tel: +44 (0) 1283 495010. About Synairgen Jan 13, 2021 · Synairgen’s SG018 trial is a randomised placebo-controlled study being conducted in approximately 20 countries enrolling a total of 610 COVID-19 patients who require supplemental oxygen. com Jul 20, 2020 · Synairgen Plc said on Monday its drug helped reduce the risk of severe cases in hospitalised patients with COVID-19, according to data from a trial of more than 100 people in the United Kingdom Consilium Strategic Communications (Financial Media and Investor. Summary Jul 24, 2019 · Synairgen plc (' Synairgen ' or the 'Company') Consilium Strategic Communications (Financial Media and Investor. John Ward, Finance Director. Geoff Nash, James Thompson (Corporate Finance) Stephen Norcross, Simon Johnson (Corporate Broking) Tel: + 44 (0) 20 7220 0500 Consilium Strategic Communications (Financial Media and Investor Relations) The latest Synairgen Open offer Assured Line share price. 3 Apr 2020 T +44 (0)20 7227 2700 | E [email protected] Live SNG RNS. Securities and Exchange Commission. Tel: + 44 (0) 23 8051 2800 . Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] Jan 20, 2021 · Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs [email protected] [email protected] finnCap Geoff Nash, Kate Bannatyne, Charlie Beeson (Corporate Finance) Alice Lane, Manasa Patil (ECM) Tel: + 44 (0) 20 7220 0500. comSophie Beaumont [email protected] Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser [email protected] Relations) May 26, 2020 · Synairgen plc Richard Marsden, Chief Executive Officer John Ward, Finance Director Tel: + 44 (0) 23 8051 2800. Initiation of the first SG018 sites had started in the UK, with dosing expected to begin As announced by Synairgen on 25 January 2021, ACTIV is a public-private partnership to develop a coordinated research strategy to speed up the development of the most promising COVID-19 treatments Jan 13, 2021 · Press release Synairgen plc(‘Synairgen' or the ‘Company') (Financial Media and Investor Relations) Mary-Jane Elliott, Olivia Manser, Carina Jurs [email protected] Tel: +44 (0) 20 3709 5700 . Richard Marsden, Chief Executive Officer. Copies of the Report and accounts can be   The most recent investor presentation can be found here. ACTIV partnership is funded by “Operation Warp Speed”, led by the US Government’s Department of Health and Human Services and designed to speed up the development of the most promising treatments and vaccine candidates for COVID-19. Synairgen is quoted on AIM (LSE: SNG). Synairgen Financial Calendar. Synairgen PLC (LON:SNG) Share Price and News. In these rules, we refer to ourselves Mar 04, 2021 · Investor Relations Global Contacts MarketWatch Synairgen's stock has soared 763. com Tel: +44 (0) 20 3709 5700 Notes for Editors Sep 29, 2020 · Press release. John Ward, Finance Director. The broader S&P 500 is up 27. Synairgen selects Parexel Biotech for global study to evaluate interferon beta compound. com Mobile: +33 (0)6 27 74 74 49Investor Feb 14, 2021 · Biophytis Investor Relations ContactMedia Contact Evelyne Nguyen – CFOLifeSci Advisors Evelyne. m. (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser. com 607-351-7812 Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs, Alex Bridge [email protected] Relations) RNS Number: 0893 J Synairgen plc 18 December 2020 Press release. com Tel: +44 (0) 20 3709 5700. Tel: +44 (0) 20 3709 5700 13. 15 Feb 2021 Press release Synairgen plc('Synairgen' or the 'Company') Consilium Strategic Communications (Financial Media and Investor Relations) 20 Jan 2021 Press release Synairgen plc('Synairgen' or the 'Company') Synairgen announces completion of recruitment into its Phase II Home-Based Consilium Strategic Communications (Financial Media and Investor Rela 26 Mar 2020 Investegate announcements from Synairgen plc, Result of Fundraising. Geoff Nash, James Thompson (Corporate Finance) Stephen Norcross, Simon Johnson (Corporate Broking) Tel: + 44 (0) 20 7220 0500 Consilium Strategic Communications (Financial Media and Investor. com Tel: +44 (0) 20 3709 5700 Notes for Editors Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Sue Stuart, Olivia Manser, Carina Jurs, Alex Bridge [email protected] synairgen investor relations